This study is an open label, single arm, pharmacokinetic trial. A total of 20 participants (children ≤12kg and >28 days old) will be enrolled. Enrollment will be competitive between Thailand and Vietnam study sites (each site will enroll as many patients that are eligible until the sample size is reached). Tafenoquine will be given concomitantly with the schizonticidal agent, chloroquine, on the day of enrolment. The participant will be admitted to hospital for observation and until the malaria smear is negative for asexual parasites on 2 consecutive days or until the schizonticidal treatment is completed, which will be approximately 3-7 days. All treatment doses will be supervised. Follow up will continue on days 7, 14, 21, and 28 then every month until month 4. Parent/guardian of participants will be instructed to follow up in between visits if participants are feeling unwell. Participants who are lost to follow up (any missed visit), who require drug re-administration after vomiting, or where at least 3 pharmacokinetic samples are not successfully drawn, will be replaced. Participants being replaced will continue in the study for safety assessments and to ensure the treatment of recurrences. The total blood drawn for this study will be 3.76 mL if the participant has no recurrences.

Start Date01 Sep 2026

Sponsor / Collaborator

University of Oxford

[+1]

NCT07060794

/ Not yet recruitingPhase 4IIT

Tafenoquine and ACTs (TADORE- Plus)

A trial designed to determine whether there is a clinically significant drug-drug interaction of tafenoquine with DHA-piperaquine or artesunate-pyronaridine using a control arm with radical cure given at the end of follow up (delayed radical cure).

Start Date01 Jun 2026

Sponsor / Collaborator

Menzies School of Health Research

NCT07373743

/ Not yet recruitingEarly Phase 1IIT

Pharmacokinetic (PK) Study of Tafenoquine in Healthy Adults

The goal of this clinical trial is to learn how people's different genetic makeups affects how their bodies convert the FDA approved drug ARAKODA (tafenoquine) to its active form. Tafenoquine is a drug that is taken to prevent malaria for people traveling to areas where there is malaria. This trial will be in healthy participants age 18-65.

Start Date01 May 2026

Sponsor / Collaborator

SUNY Upstate Medical University

100 Clinical Results associated with Tafenoquine Succinate

100 Translational Medicine associated with Tafenoquine Succinate

100 Patents (Medical) associated with Tafenoquine Succinate

358

Literatures (Medical) associated with Tafenoquine Succinate

01 Aug 2026·ACTA TROPICA

Efficacy of delayed tafenoquine administration for radical cure of Plasmodium vivax Malaria: A systematic review

Review

Author: DeVita, Timothy N ; Gutman, Julie R ; Chang, Michelle A ; Williams, Seymour ; Hwang, Jimee ; Ridpath, Alison D

Malaria remains a significant global public health challenge. Among the causative species, Plasmodium vivax and Plasmodium ovale can form dormant liver stages known as hypnozoites, which require additional treatment to prevent relapse of the disease. Currently in the U.S., the only available anti-relapse therapies are single-dose tafenoquine (TQ) and a 14-day course of primaquine. Both medications carry the risk of hemolysis in patients with glucose-6-phosphate-dehydrogenase (G6PD) deficiency, necessitating G6PD testing before administering. Moreover, TQ is approved only for coadministration with chloroquine, limiting its use when G6PD testing is delayed or unavailable. We conducted a systematic review assessing the efficacy of a single dose of TQ (≥300 mg) administered three or more days (delayed) after initiation of chloroquine/hydroxychloroquine for blood stage malaria in patients with confirmed infection. Five databases (Medline, Embase, Cochrane, CINAHL, and Scopus) and one register (Clinicaltrials.gov) were searched through January 2026 yielding 394 unique articles. Two randomized, open-label trials (conducted 1996-1999) met inclusion criteria; both evaluated single-dose TQ (500 or 600 mg) administered on Day 4 or Day 6 following a 3-day chloroquine course. Based on limited data from trials that used higher than currently recommended TQ doses, we conclude that there is insufficient evidence to definitively recommend for or against delayed TQ administration. However, the data does suggest that delayed TQ is likely better than treatment with chloroquine alone and could be a preferable option to the 14-day primaquine regimen in situations where adherence is unlikely. Clinicians should weigh risks and benefits of each regimen in collaborations with their patients to determine the most appropriate treatment approach.

03 Jun 2026·ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Differential impact of Tafenoquine and Primaquine on Plasmodium vivax recurrence: the role of CYP2D6 variants

Article

Author: Godinho, Vanessa Karina Castro ; Mwangi, Victor Irungu ; Trindade Maranhão Costa, Fabio ; Alves, Jessica Rafaela dos Santos ; Brito, Marcelo Augusto Mota ; Almeida, Anne Cristine Gomes de ; Lacerda, Marcus Vinicius Guimarães de ; Morais, Manuela Crispim ; Melo, Gisely Cardoso de ; Lopes, Adriana Patricia Brelaz

ABSTRACT:

Malaria, particularly by Plasmodium vivax , remains a significant public health challenge in endemic regions. P. vivax has the dormant liver-stage hypnozoites that can reactivate, causing relapses, even after the initial blood-stage infection has been cleared. The prevention of these relapses hinges on the use of 8-aminoquinolines such as primaquine (PQ) and tafenoquine (TQ). However, the efficacy of these treatments is associated with Cytochrome P450 2D6 ( CYP2D6 ) activity, which influences drug metabolism. This case-control study aimed to evaluate the relationship between CYP2D6 activity and the efficacy of TQ and PQ in preventing P. vivax relapses. Patients with P. vivax malaria were included in a nested case-control cohort study conducted at the Fundação de Medicina Tropical Dr. Heitor Vieira Dourado (Manaus, AM, Brazil). Participants were classified as cases (recurrent malaria within 180 days) or controls (patients without recurrence). They were treated with PQ or TQ. Epidemiological data were collected from participants, and blood samples were obtained for CYP2D6 genotyping by real-time PCR. The results showed that CYP2D6 polymorphisms did not affect TQ efficacy ( P = 0.172). However, participants treated with PQ had a higher risk of recurrence until six months ( P = 0.016). Those with a predicted intermediate or poor metabolizer phenotype (gIM + gPM) were more likely to experience recurrence compared to normal metabolizers (gNM) ( P = 0.036). Our findings indicate that CYP2D6 does not impact the efficacy of TQ, whereas P. vivax recurrence is associated with predicted metabolic phenotype, with increased risk among patients treated with PQ, suggesting that CYP2D6 variability influences treatment response, particularly in intermediate/poor metabolizers.

01 Jun 2026·BMJ Global Health

Risk perceptions of high-dose primaquine and tafenoquine among Plasmodium vivax malaria stakeholders in Ethiopia: a qualitative study

Article

Author: Kejela, Muhaba ; Korra, Kansite Gellebo ; Thriemer, Kamala ; Engel, Nora ; Krumeich, Anja ; Ley, Benedikt ; Mwaura, Muthoni ; Wodaj, Tsegabehan ; Shibiru Degaga, Tamiru ; Price, Ric

Background:

Adherence to radical cure for Plasmodium vivax remains a major challenge for malaria control programmes. Novel regimens, such as 7-day high-dose primaquine regimen and single-dose tafenoquine, may improve treatment adherence and antirelapse effectiveness but can increase the risk of haemolysis in individuals with glucose-6-phosphate dehydrogenase deficiency. Stakeholder (ie, policymakers, providers, patients, etc) perceptions of these risks may significantly influence the acceptability and uptake of these regimens. Understanding these perceptions is essential for policymakers to design effective communication and implementation strategies of novel radical cure strategies.

Methods:

Guided by qualitative methodology and a risk perception lens, this study explored P. vivax malaria stakeholders’ experiences and interpretations of novel radical cure regimens. Between February and September 2023, 58 semistructured interviews and 6 focus group discussions were conducted at Arba Minch General Hospital and three health centres and health posts within the Gamo Zone of the South Ethiopia Regional State: Lante, Shecha and Shele. Participants included clinical trial staff and participants, health centre personnel, health extension workers and routine care patients.

Results:

The 7-day-high-dose primaquine regimen and single-dose tafenoquine were viewed as promising solutions to the adherence challenges of the standard 14-day primaquine regimen; however, participants raised concerns about the effectiveness of the shortened treatment duration and the safety of the increased daily dose of primaquine. A risk perception lens revealed that concerns about effectiveness and safety were influenced by prior public health messaging emphasising completion of the full 14-day regimen alongside fears of overdosing and drug-induced haemolysis. Pill characteristics, including number, shape and colour as well as fears of overdosing and drug-induced haemolysis also contributed to apprehension about the safety of these regimens.

Conclusion:

Participants’ perceptions of shortened radical cure regimens were shaped by concerns about effectiveness and safety, influenced by prior treatment messaging and pill characteristics such as higher dosing and pill burden. A risk perception lens can inform implementation and communication strategies for novel regimens, where addressing user perceptions alongside practical improvements, such as reducing pill burden, is essential for optimising uptake and adherence.

News (Medical) associated with Tafenoquine Succinate

03 Sep 2026

·www.biospace.com

60 Degrees Pharmaceuticals Announces Participation in H.C. Wainwright 28th Annual Global Investment Conference

– On-demand company presentation will be available beginning September 11, 2026, at 7:00 a.m. ET – – Management will be available for one-on-one investor meetings during the conference – WASHINGTON, Sept. 03, 2026 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (“60 Degrees Pharma” or the “Company”), a pharmaceutical company focused on developing new medicines for vector-borne diseases, today announced that management will participate in the H.C. Wainwright 28th Annual Global Investment Conference, taking place September 14-16, 2026, in New York City. A pre-recorded presentation by 60 Degrees Pharmaceuticals will be available on demand here to registered conference attendees and the general public beginning Friday, September 11, 2026, at 7:00 a.m. ET through the H.C. Wainwright conference portal. ezstandalone.cmd.push(function () { ezstandalone.showAds(131); }); The presentation will provide an overview of 60 Degrees Pharmaceuticals and its programs focused on the development and commercialization of medicines for vector-borne diseases. Management will also be available for one-on-one meetings with institutional investors and other conference participants during the conference. Investors interested in scheduling a meeting with 60 Degrees Pharmaceuticals are encouraged to submit a meeting request through the H.C. Wainwright conference platform. Presentation Details Conference: H.C. Wainwright 28th Annual Global Investment Conference Presentation: Pre-recorded, on-demand presentation Available: Friday, September 11, 2026, beginning at 7:00 a.m. ET Conference Dates: September 14-16, 2026 Location: Lotte New York Palace Hotel, New York City Investor Meetings: Management available for one-on-one meetings during the conference ezstandalone.cmd.push(function () { ezstandalone.showAds(132); }); About 60 Degrees Pharmaceuticals, Inc. 60 Degrees Pharmaceuticals, Inc., founded in 2010, develops and commercializes new medicines for the treatment and prevention of vector-borne disease. The Company won U.S. Food and Drug Administration approval of its lead product, ARAKODA® (tafenoquine), for malaria prevention in 2018 and currently has 3 active clinical trials underway for babesiosis, an emerging tick-borne disease. ARAKODA is sold commercially in the U.S. and Australia. 60 Degrees also collaborates with prominent research and academic organizations in the U.S. and Australia to advance science around vector-borne disease. The Company is headquartered in Washington, D.C., with a subsidiary in Australia. Learn more at . Cautionary Note Regarding Forward-Looking Statements This press release may contain “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward‐looking statements reflect the current view about future events. When used in this press release, the words “anticipate,” “believe,” “estimate,” “expect,” “future,” “intend,” “plan,” or the negative of these terms and similar expressions, as they relate to us or our management, identify forward‐looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy, activities of regulators and future regulations and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: there is substantial doubt as to our ability to continue on a going-concern basis; we might not be eligible for Australian government research and development tax rebates; if we are not able to successfully develop, obtain FDA approval for, and provide for the commercialization of non-malaria prevention indications for tafenoquine (ARAKODA® or other regimen) or Celgosivir in a timely manner, we may not be able to expand our business operations; we may not be able to successfully conduct planned clinical trials; and we have no manufacturing capacity which puts us at risk of lengthy and costly delays of bringing our products to market. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (“SEC”), including the information contained in our Annual Report on Form 10-K filed with the SEC on March 30, 2026, and our subsequent SEC filings. Investors and security holders are urged to read these documents free of charge on the SEC’s web site at . As a result of these matters, changes in facts, assumptions not being realized or other circumstances, the Company’s actual results may differ materially from the expected results discussed in the forward-looking statements contained in this press release. Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise. ezstandalone.cmd.push(function () { ezstandalone.showAds(133); }); Media Contact: Kristen Landon kristenlandon@60degreespharma.com Investor Contact: Patrick Gaynes patrickgaynes@60degreespharma.com

Drug Approval

14 Aug 2026

·investors.60degreespharma.com

60 Degrees Pharmaceuticals Announces Second Quarter 2026 Results

WASHINGTON, Aug. 14, 2026 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (the “Company”), a pharmaceutical company focused on developing new medicines for vector-borne diseases, reported today its financial results for the second quarter of 2026, ended June 30, 2026. Financial Highlights for the Quarter Ended June 30, 2026: Net product revenues increased approximately 106% to approximately $208 thousand for the second quarter of 2026, from approximately $101 thousand for the second quarter of 2025. Gross profit on product revenues was approximately $57 thousand for the second quarter of 2026, compared with approximately $51 thousand for the second quarter of 2025. Operating expenses were approximately $2.33 million for the second quarter of 2026, compared with approximately $1.86 million for the second quarter of 2025. Net loss attributable to common stockholders was approximately $2.40 million, or $0.90 per share, for the second quarter of 2026, compared with a net loss of approximately $1.84 million, or $5.01 per share, for the second quarter of 2025. Additional information regarding the Company's results is available in its Quarterly Report on Form 10-Q for the quarter ended June 30, 2026. About 60 Degrees Pharmaceuticals, Inc. 60 Degrees Pharmaceuticals, Inc., founded in 2010, develops and commercializes new medicines for the treatment and prevention of vector-borne disease. The Company won U.S. Food and Drug Administration approval of its lead product, ARAKODA® (tafenoquine), for malaria prevention in 2018 and currently has 3 active clinical trials underway for babesiosis, an emerging tick-borne disease. ARAKODA is sold commercially in the U.S. and Australia. 60 Degrees also collaborates with prominent research and academic organizations in the U.S. and Australia to advance science around vector-borne disease. The Company is headquartered in Washington, D.C., with a subsidiary in Australia. Learn more at www.60degreespharma.com. Cautionary Note Regarding Forward-Looking Statements This press release may contain “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward‐looking statements reflect the current view about future events. When used in this press release, the words “anticipate,” “believe,” “estimate,” “expect,” “future,” “intend,” “plan,” or the negative of these terms and similar expressions, as they relate to us or our management, identify forward‐looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy, activities of regulators and future regulations and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: there is substantial doubt as to our ability to continue on a going-concern basis; we might not be eligible for Australian government research and development tax rebates; if we are not able to successfully develop, obtain FDA approval for, and provide for the commercialization of non-malaria prevention indications for tafenoquine (ARAKODA® or other regimen) or Celgosivir in a timely manner, we may not be able to expand our business operations; we may not be able to successfully conduct planned clinical trials; and we have no manufacturing capacity which puts us at risk of lengthy and costly delays of bringing our products to market. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (“SEC”), including the information contained in our Annual Report on Form 10-K filed with the SEC on March 30, 2026, and our subsequent SEC filings. Investors and security holders are urged to read these documents free of charge on the SEC’s web site at www.sec.gov. As a result of these matters, changes in facts, assumptions not being realized or other circumstances, the Company’s actual results may differ materially from the expected results discussed in the forward-looking statements contained in this press release. Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise. Media Contact: Kristen Landon kristenlandon@60degreespharma.com Investor Contact: Patrick Gaynes patrickgaynes@60degreespharma.com

Financial StatementDrug Approval

30 Jul 2026

·www.biospace.com

60 Degrees Pharmaceuticals, Inc. Announces Private Placement Priced At-the-Market Under Nasdaq Rules

WASHINGTON, July 30, 2026 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP, SXTPW) (“60 Degrees” or the “Company”), a pharmaceutical company that develops and commercializes new medicines for vector-borne disease, today announced that it has entered into definitive agreements for the issuance and sale of an aggregate of 574,713 shares of its common stock (or pre-funded warrants in lieu thereof), series A warrants to purchase up to 574,713 shares of common stock and short-term series B warrants to purchase up to 574,713 shares of common stock at a purchase price of $1.74 per share (or per pre-funded warrant in lieu thereof) and accompanying warrants in a private placement priced at-the-market under Nasdaq rules. The series A warrants and short-term series B warrants will have an exercise price of $1.49 per share and will be exercisable upon issuance. The Series A warrants will expire five years from the effective date of the Resale Registration Statement (as defined below) and the short-term Series B warrants will expire twenty-four months from the effective date of the Resale Registration Statement. The closing of the offering is expected to occur on or about July 31, 2026, subject to the satisfaction of customary closing conditions. H.C. Wainwright & Co. is acting as the exclusive placement agent for the private placement. The gross proceeds to 60 Degrees from the offering are expected to be approximately $1.0 million, before deducting the placement agent’s fees and other offering expenses payable by 60 Degrees, and excluding the proceeds, if any, from the exercise of the warrants. The Company intends to use the net proceeds from this offering for working capital and general corporate purposes. The securities described above are being offered in a private placement under Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”), and/or Regulation D promulgated thereunder and, along with the shares of common stock underlying the warrants, have not been registered under the Securities Act, or applicable state securities laws. Accordingly, the securities described above, including the shares of common stock underlying the warrants, may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws. Pursuant to a registration rights agreement, the Company has agreed to resale registration statement covering the securities described above (the “Resale Registration Statement”). ezstandalone.cmd.push(function () { ezstandalone.showAds(131); }); This press release does not constitute an offer to sell or a solicitation of an offer to buy the securities in this offering, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction. About 60 Degrees Pharmaceuticals, Inc. 60 Degrees Pharmaceuticals, Inc., founded in 2010, specializes in developing and commercializing new medicines for the treatment and prevention of vector-borne disease. The Company achieved U.S. Food and Drug Administration approval of its lead product, ARAKODA® (tafenoquine), for malaria prevention, in 2018. ARAKODA is commercially available in the U.S. and Australia. 60 Degrees Pharmaceuticals, Inc. also collaborates with prominent research and academic organizations in the U.S. and Australia. 60 Degrees Pharmaceuticals, Inc. is headquartered in Washington, D.C., with a subsidiary in Australia. Learn more at Cautionary Note Regarding Forward-Looking Statements This press release may contain "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward‐looking statements reflect the current view about future events, which include, among others, statements related to the completion of the private placement, the satisfaction of customary closing conditions related to the private placement and the intended use of proceeds from the private placement. When used in this press release, the words "anticipate," "believe," "estimate," "expect," "future," "intend," "plan," or the negative of these terms and similar expressions, as they relate to us or our management, identify forward‐looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy, activities of regulators and future regulations and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: there is substantial doubt as to our ability to continue on a going-concern basis; we might not be eligible for Australian government research and development tax rebates; if we are not able to successfully develop, obtain FDA approval for, and provide for the commercialization of non-malaria prevention indications for tafenoquine (ARAKODA® or other regimen) or castanospermine in a timely manner, we may not be able to expand our business operations; we may not be able to successfully conduct planned clinical trials or patient recruitment in our trials might be slow or negligible; and we have no manufacturing capacity which puts us at risk of lengthy and costly delays in bringing our products to market, and general market and other conditions. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings with the Securities and Exchange Commission ("SEC"), including the information contained in our Annual Report on Form 10-K for the fiscal year ended December 31, 2025 filed with the SEC on March 30, 2026, and our subsequent SEC filings. Investors and security holders are urged to read these documents free of charge on the SEC's website at As a result of these matters, changes in facts, assumptions not being realized or other circumstances, the Company's actual results may differ materially from the expected results discussed in the forward-looking statements contained in this press release. Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise, except as required by law. Media Contact: Kristen Landon kristenlandon@60degreespharma.com Investor Contact: Patrick Gaynes patrickgaynes@60degreespharma.com

Drug Approval

100 Deals associated with Tafenoquine Succinate

External Link

KEGG	Wiki	ATC	Drug Bank
D10670	Tafenoquine Succinate	P01BA07	DB06608

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Malaria	United States	60 Degrees Pharmaceuticals, Inc.	08 Aug 2018
Malaria, Vivax	United States	GlaxoSmithKline Intellectual Property Development Ltd.	20 Jul 2018

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Hemolysis	Phase 3	Brazil	GSK Plc	30 Apr 2015
Hemolysis	Phase 3	Colombia	GSK Plc	30 Apr 2015
Hemolysis	Phase 3	Ethiopia	GSK Plc	30 Apr 2015
Hemolysis	Phase 3	Peru	GSK Plc	30 Apr 2015
Hemolysis	Phase 3	Thailand	GSK Plc	30 Apr 2015
Hemolysis	Phase 3	Vietnam	GSK Plc	30 Apr 2015
Fatigue	Phase 2	United States	60 Pharmaceuticals LLC	18 Nov 2025
Babesiosis	Phase 2	United States	60 Pharmaceuticals LLC	17 Jun 2024
COVID-19	Phase 2	United States	60 Pharmaceuticals LLC	19 Feb 2021
Malaria, Falciparum	Phase 2	-	Smithkline Beecham	01 May 2000

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04411836 (EFFORT, Pubmed \| Lancet Infect Dis)	Phase 3	Malaria, Vivax	960	7-day high-dose primaquine	cfvmtrvdnh(ernrkzsqlf) = cumardqzca khvpsoqefl (lwicofqeeh ) View more	Positive	01 Jun 2026
				Tafenoquine	cfvmtrvdnh(ernrkzsqlf) = mmwygbwhgp khvpsoqefl (lwicofqeeh )
NCT03320174 (CTgov)	Phase 2	-	600	Tafenoquine (Tafenoquine 200 mg (2 x 100 mg Tablets))	afeuqvgiyl = rnzdkisetu hzelwakrqd (pgfwascwtr, wepfnukfgd - mkpuzzvbxo) View more	-	17 Apr 2026
				Placebo (Placebo)	afeuqvgiyl = bjfiacotdu hzelwakrqd (pgfwascwtr, iecympflxk - tblvxoepgz) View more
NCT06478641 (Company_Website) Manual	Not Applicable	Babesiosis	1	Tafenoquine	bnsfvbqrsl(getoimnpuc) = jqvkjunurf cifeiuutyf (qktytsrikc )	Positive	15 Oct 2025
NCT04533347 (CTgov)	Phase 2	COVID-19	86	Tafenoquine Oral Tablet (Tafenoquine)	gtfkymmhyd: P-Value = 0.1879	-	07 Jan 2025
				Placebo (Placebo)
NCT05096702 (Pubmed \| Lancet Infect Dis)	Not Applicable	Malaria, Vivax glucose-6-phosphate dehydrogenase (G6PD)	5,554	Tafenoquine 300 mg	cvjawmykwl(dtkibusnar) = bcfkbvpahf kuqixmowkv (ouknpgtgdf, 76 - 120)	Positive	01 Jun 2024
				7-day Primaquine 0.5 mg/kg per day	cvjawmykwl(dtkibusnar) = gefnejncbb kuqixmowkv (ouknpgtgdf, 52 - 94)
ACTRN12620000995976 (Australian and New Zealand Clinical Trials Registry, Pubmed \| Clin Infect Dis)	Phase 1	Malaria \| Infectious Diseases glucose 6-phosphate dehydrogenase (G6PD)	12	Tafenoquine 200 mg	fmspvcoyup(arjzjhihqa) = ogiabfqohc ndvtnkcfne (ahhjbcuzlb )	Positive	08 Jun 2023
				Tafenoquine 300 mg	fmspvcoyup(arjzjhihqa) = zjmlaqpwly ndvtnkcfne (ahhjbcuzlb )
NCT02802501 (200894, Pubmed \| Lancet Infect Dis)	Phase 3	Malaria, Vivax	150	Dihydroartemisinin-piperaquine alone	logfpdbvrs(johvsdqlhs) = objsqpoijy ywbbhrtmnx (tkkgnznfec, 4 - 22)	Negative	23 May 2023
				Dihydroartemisinin-piperaquine plus tafenoquine	logfpdbvrs(johvsdqlhs) = fpkjqtsrin ywbbhrtmnx (tkkgnznfec, 11 - 34)
NCT05788094 (Pubmed)	Phase 4	Malaria, Vivax	-	Tafenoquine 5 mg/kg	owljjkqdtk(lwgqbnemks) = nqzdttbimi pfufbkwqcl (abvdemwkwn )	-	06 Dec 2022
				Tafenoquine 7.5 mg/kg	owljjkqdtk(lwgqbnemks) = pyyvkgxtqv pfufbkwqcl (abvdemwkwn )
NCT03320174 (Pubmed \| Travel Med Infect Dis)	Phase 2	-	600	Tafenoquine 200mg	onaakeqvhb(wlmecwlujr) = ocggfpeeqc qzedbdtjrc (eswncfswog ) View more	-	01 Jan 2022
				Placebo	onaakeqvhb(wlmecwlujr) = yiymkbqige qzedbdtjrc (eswncfswog ) View more
NCT02563496 (TEACH \| TAF113577, Corporate Publications) Manual	Phase 2	Malaria, Vivax	60	Tafenoquine Succinate	ethkmlgntm(ncwmwwcktg) = bnsmntafcc jqfvdcyjwt (uxodrtpofa ) View more	Positive	19 Nov 2020

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis